Drugs / COVI-GUARD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04454398 | Sep 2020 → Jan 2021 | COVID-19 | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVI-GUARD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04454398 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody” NCT04454398 ↗ |
| Route | Intravenous | “administered via a single IV push injection” NCT04454398 ↗ |